Summary
Amgen Inc. reported strong performance in its 2023 Annual Report, highlighted by a significant increase in total product sales, primarily driven by volume growth in key products like Repatha, TEZSPIRE, EVENITY, Prolia, and BLINCYTO. The acquisition of Horizon Therapeutics plc in October 2023 for $27.8 billion was a major strategic move, bolstering Amgen's rare disease portfolio with the addition of TEPEZZA, KRYSTEXXA, and UPLIZNA. Despite a decline in sales for certain established products like ENBREL and Neulasta due to increased competition and pricing pressures, Amgen's overall revenue grew. The company is actively managing its pipeline, with promising developments in its Phase 3 programs and an increased focus on human genetics and innovative technologies. Amgen also continues its commitment to returning capital to shareholders through dividends and share repurchases, while navigating a complex regulatory and reimbursement landscape, including the ongoing tax dispute with the IRS.
Financial Highlights
56 data points| Revenue | $28.19B |
| Cost of Revenue | $8.45B |
| Gross Profit | $19.74B |
| SG&A Expenses | $6.18B |
| Operating Expenses | $20.29B |
| Operating Income | $7.90B |
| Interest Expense | $2.88B |
| Net Income | $6.72B |
| EPS (Basic) | $12.56 |
| EPS (Diluted) | $12.49 |
| Shares Outstanding (Basic) | 535.00M |
| Shares Outstanding (Diluted) | 538.00M |
Key Highlights
- 1Completed the acquisition of Horizon Therapeutics plc in October 2023 for $27.8 billion, significantly strengthening its rare disease portfolio with products like TEPEZZA, KRYSTEXXA, and UPLIZNA.
- 2Total product sales increased by 9% to $26.9 billion, driven by volume growth in Repatha, TEZSPIRE, EVENITY, Prolia, and BLINCYTO, along with initial sales from the Horizon acquisition.
- 3Operating income decreased by 17% to $7.9 billion, primarily due to higher amortization and acquisition-related expenses from the Horizon acquisition.
- 4Net income increased by 3% to $6.7 billion, resulting in diluted EPS of $12.49.
- 5R&D expenses increased by 8% to $4.8 billion, with higher spending on later-stage clinical programs and marketed product support.
- 6The company's pipeline advanced, with 24 Phase 3 programs as of January 31, 2024, up from 18 in the prior year, indicating continued investment in future growth.
- 7Amgen faces ongoing competition from biosimilars and generics, particularly impacting established products like ENBREL and Neulasta, leading to net price declines.